Experts say gene therapy had learned its lessons- and is poised for a breakthrough
1/19/2005 Robert Cooke Newsday.com - Health/Science The experiment was daring - squared. Two brave little Ohio girls underwent the world's first authorized gene therapy experiment - an attempt to give them functioning immune systems for the rest of their lives. The procedure delivered new, corrective genes into their white blood cells, using a virus as the delivery vehicle. That was 15 years ago. Today, both are college students. Without those new genes, it was unlikely they could have survived in a world of germs - even if sheltered inside huge plastic bubbles. Their survival signaled the advent of a promising frontier, one designed to repair genetic flaws behind life-threatening disorders. But after 5,000 patients had participated in 350 trials, things began to go wrong. First, in 1999, a young man being treated by the University of Pennsylvania died of a massive immune reaction to the gene treatment for a rare metabolic disorder. Three years later, a French baby was successfully treated for the same disorder the Ohio girls had, but developed leukemia as a byproduct of the treatment. The next year, a second French child did likewise. Researchers called a timeout. Today, a leading researcher says those downturns have provided a reason for optimism: They taught valuable lessons and, as a result, gene therapy is poised for a renaissance. The expert, Dr. Savio Woo, said that today researchers not only understand what triggered leukemia in the two children, but also are emboldened because the therapy itself has proven a success. [...]